SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

Auryxia

AKBA·Akebia Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since September 2014.
Why 4/10
Auryxia is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst is the Q4 2026 earnings report (expected early March 2027) showing the pace of generic erosion, but quarterly sales are not a binary catalyst. ImpactScore is 4 because the drug is an approved, revenue-generating product in decline with no upcoming binary event.
Actionable Insight NEUTRAL

Auryxia has no upcoming binary catalyst; its revenue trajectory is a steady decline driven by Teva's generic entry in March 2026. The next meaningful event for Akebia as a whole is the January 2027 expiration of Vafseo's TDAPA transitional add-on payment, which could pressure Vafseo pricing. Investors should watch Q4 2026 Auryxia revenue (expected in early March 2027) to gauge the pace of generic erosion.

Price Chart

Loading chart...

Executive Summary

Auryxia (ferric citrate) is an FDA-approved oral phosphate binder and iron replacement therapy for chronic kidney disease patients, originally approved in 2014 and expanded to a second indication in 2017. The drug is now in commercial decline: Teva launched a generic version in March 2026, and Auryxia's quarterly net revenue has fallen from $42.5 million (Q3 2025) to $20.0 million (Q3 2026). Akebia Therapeutics is pivoting its commercial focus to Vafseo (vadadustat), a newer anemia drug for dialysis patients. For an investor, Auryxia is a mature, declining asset with no upcoming binary catalyst; the stock's thesis increasingly depends on Vafseo's commercial trajectory rather than Auryxia.

How It Works

Auryxia (ferric citrate) is an oral iron-based tablet that works as a phosphate binder. In the stomach, it binds to phosphorus from food, preventing it from being absorbed into the bloodstream and allowing it to exit the body through waste. This lowers serum phosphorus levels in kidney dialysis patients. Separately, the iron in the drug can be absorbed to treat iron deficiency anemia in chronic kidney disease patients not on dialysis.

Trial Status

Auryxia is FDA-approved and commercially marketed. No active clinical trials are required for this drug; Akebia's pipeline focus has shifted to Vafseo (vadadustat) and rare kidney disease assets.

The Two-Sided Case

▲ Bull Case4
Auryxia remains FDA-approved for two indications (hyperphosphatemia in dialysis CKD, and iron deficiency anemia in non-dialysis CKD), providing a dual-label advantage over some phosphate binders.
Despite generic pressure, Auryxia still generated $20 million in Q3 2026 revenue, contributing cash flow that helps fund Akebia's transition to its next-generation product Vafseo.
Analyst consensus on AKBA remains bullish (10 analysts: 4 strong buy, 6 buy, 2 hold) with a mean price target of $3.92, implying roughly 820% upside from the current ~$0.40 share price.
Some institutional investors added or doubled AKBA positions in Q2 2026, including Jacobs Levy (+894%), Ameriprise (+5,926%), and Millennium Management (+34%).
▼ Bear Case5
Teva launched a generic version of ferric citrate on March 11, 2026, directly competing on price and eroding Auryxia's market share rapidly.
Auryxia Q3 2026 net revenue fell 53% year-over-year to $20.0 million (from $42.5 million), and the company expects further declines in 2026.
Akebia swung to a $14.4 million net loss in Q3 2026 from a $0.5 million profit a year earlier, driven largely by Auryxia's decline.
Several large institutional holders trimmed or exited AKBA positions in Q2/Q3 2026, including State Street (trimmed 53.6%), Citigroup (near-exit), and Bank of America (near-exit).
The phosphate binder market is crowded with branded and generic alternatives (sevelamer, lanthanum, calcium-based binders), limiting Auryxia's pricing power even before generic entry.

Upcoming Catalysts

  • Q4 2026 earnings report (expected early March 2027) showing the pace of Auryxia generic erosion
  • January 2027 expiration of Vafseo's TDAPA add-on payment, which could affect combined product revenue dynamics

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Akebia Therapeutics, Inc. PRESS-RELEASE AKBA ·Originating report

Sources · 10

Hover a chip for the title
1 ir.akebia.com2 markets.businessinsider.com3 drugpatentwatch.com4 tradingkey.com5 stocktitan.net6 ir.akebia.com7 marketbeat.com8 drugs.com9 auryxiahcp.com10 sec.gov